European Companies Search Engine

Tips & Tricks
Our help pages Using the Quick Search and Power Search Overview explain how to use our search engine.

X4 Pharmaceuticals (Austria) GmbH, Vienna, Austria

Watch

If you put a company on your watch list, we'll notify you on your email address when there are new publications regarding this company.

This feature is only available to our premium service subscribers.

Learn more about the North Data Premium Service

Dossier

The dossier is a printable PDF file, summarizing information and publications for this company. The creation of dossiers is included in your subscription. After the creation of the dossier is completed, it will be sent to your email address .

Add to dossier (if available):

This feature is only available to our premium service subscribers.

Learn more about the North Data Premium Service

Name

X4 Pharmaceuticals (Austria) GmbH
ARSANIS Biosciences GmbH
Arsanis Arzneimittelforschung GmbH

Identification

Fb
Firmenbuch 354305m
EUID
ATBRA.354305-000

Address

Hohenstaufengasse 9/DG, 1010 Wien, Austria

Financial performance

Earnings

For this company, Earnings numbers are only available to our premium service subscribers.

Learn more about the North Data Premium Service

Revenue

For this company, Revenue numbers are only available to our premium service subscribers.

Learn more about the North Data Premium Service

History

Persons

Marketing & Tech

Network

Loading network

Legal Structure

Current legal representatives (1) · Current shareholders (1)
This feature is only available to our premium service subscribers.

Learn more about the North Data Premium Service

Financials

Key Performance Indicators: Financial (5) · Mktg & Tech (5)

The following indicators are on file for this company: Base/share capital · Total assets · Earnings · Earnings CAGR · Revenue · Revenue CAGR · Return on sales · Equity · Equity ratio · Return on equity · Employee number · Revenue per employee · Cash on hand · Receivables · Liabilities · Patents

This feature is only available to our premium service subscribers.

Learn more about the North Data Premium Service

Publications

27 Feb 2026
Managing Director: David Kirske · No longer Managing Director: Barbara Grell
5 Jul 2025
Address
25 Apr 2025
Annual report for the year ending 31/12/2024 · Balance sheet for 31/12/2024
1 Jun 2024
Annual report for the year ending 31/12/2023
23 Mar 2023
Annual report for the year ending 31/12/2022 · Balance sheet for 31/12/2022
30 Jun 2022
Annual report for the year ending 31/12/2021 · Balance sheet for 31/12/2021
9 Sept 2021
Annual report for the year ending 31/12/2020 · Balance sheet for 31/12/2020
18 Nov 2020
Annual report for the year ending 31/12/2019 · Balance sheet for 31/12/2019
30 Sept 2020
Patent: Antibodies Directed Against the Lukgh (Lukab) Toxin of Staphylococcus Aureus and Antibody Sequences
1 Jan 2020
Patent: Predicting S. Aureus Disease
3 Sept 2019
Annual report for the year ending 31/12/2018
6 Aug 2019
Managing Director: Barbara Grell · No longer Managing Director: David Scott Mantus
19 Jun 2019
Name: X4 Pharmaceuticals (Austria) GmbH
4 May 2019 as ARSANIS Biosciences GmbH
Firmenbuch - Vollzug - Republik Österreich vertreten durch das BMJ
3 Apr 2019 as ARSANIS Biosciences GmbH
No longer Managing Director: Michael P. Gray
27 Feb 2019 as ARSANIS Biosciences GmbH
Patent: E. Coli Specific Antibody Sequences
26 Dec 2018 as ARSANIS Biosciences GmbH
Patent: MDR E. Coli Specific Antigen
6 Oct 2018
Annual report for the year ending 31/12/2017 · Balance sheet for 31/12/2017
28 Jun 2018 as ARSANIS Biosciences GmbH
No longer Managing Director: Zoltán Magyarics
12 Jun 2018 as ARSANIS Biosciences GmbH
Proxy policy
9 Jun 2018 as ARSANIS Biosciences GmbH
Managing Director: Michael P. Gray
2 Jun 2018 as ARSANIS Biosciences GmbH
Managing Director: David Scott Mantus
26 May 2018 as ARSANIS Biosciences GmbH
Managing Director: Zoltán Magyarics · No longer Managing Director: Eszter Nagy
7 Mar 2018 as ARSANIS Biosciences GmbH
Patent: MDR E. Coli Specific Antibody
11 Aug 2017
Patent: Klebsiella Pneumoniae O3 Specific Antibodies
11 Aug 2017
Patent: Anti-Galactan II Monoclonal Antibodies Targeting Klebsiella Pneumoniae
23 May 2017 as ARSANIS Biosciences GmbH
Firmenbuch - Vollzug - Republik Österreich vertreten durch das BMJ
16 May 2017 as ARSANIS Biosciences GmbH
Annual report for the year ending 31/12/2016 (only announcement)
Year 2016 in Epobase
4 European patent filings: Bactericidal Monoclonal Antibody Targeting Klebsiella Pneumoniae …
2 Aug 2016 as ARSANIS Biosciences GmbH
Annual report for the year ending 31/12/2015 (only announcement)
5 Jul 2016 as ARSANIS Biosciences GmbH
State Aid (€34,319): FFG-RL SMES
5 Jul 2016 as ARSANIS Biosciences GmbH
State Aid (€550,900): FFG-RL SMES
3 Nov 2015
Patent: Antibodies Targeting a Galactan-Based O-Antigen of K. Pneumoniae
Year 2015 in Dpmap
6 patent filings: E. Coli-Spezifische Antikörpersequenzen …
3 Jun 2015 as ARSANIS Biosciences GmbH
Patent: Cross-Reactive Staphylococcus Aureus Antibody
2 Jun 2015 as ARSANIS Biosciences GmbH
Annual report for the year ending 31/12/2014 (only announcement)
17 Oct 2014
Patent: Cross-Reactive Staphylococcus Aureus Antibody Sequences
1 Oct 2014 as Arsanis Biosciences GmbH
EU funding (€50,000): Clinical biomarker and rapid diagnostic test for Staphylococcus aureus induced ventilator-associated pneumonia
16 May 2014
Patent: Generation of Highly Potent Antibodies Neutralizing the Lukgh (Lukab) Toxin of Staphylococcus Aureus
3 Apr 2014 as ARSANIS Biosciences GmbH
Annual report for the year ending 31/12/2013 (only announcement)
7 Mar 2013 as ARSANIS Biosciences GmbH
Annual report for the year ending 31/12/2012 (only announcement)
10 Mar 2012 as ARSANIS Biosciences GmbH
Annual report for the year ending 31/12/2011 (only announcement)
9 Mar 2012 as ARSANIS Biosciences GmbH
Annual report for the year ending 30/09/2011 (only announcement)
30 Dec 2011 as ARSANIS Biosciences GmbH
Deadline for annual balance: 31.12.
8 Sept 2011 as ARSANIS Biosciences GmbH
Address
30 Apr 2011 as ARSANIS Biosciences GmbH
Address · Name: ARSANIS Biosciences GmbH
2 Dec 2010 as Arsanis Arzneimittelforschung GmbH
No longer Shareholder (1) · Shareholder: X4 Pharmaceuticals Inc. · Capital: €40,000
19 Nov 2010 as Arsanis Arzneimittelforschung GmbH
Reg­is­tra­tion: 19/11/2010 · MD: Eszter Nagy · SH (1) · Address · Deadline for annual balance: 30.09. · Capital: €40,000 · Seat: Vienna, Austria · Legal form: Gesellschaft mit beschränkter Haftung
There are no publications matching your search.

The data on this page is generated by a fully automated algorithm. It may have errors, and is provided on an "as is" basis with no guarantees of completeness, accuracy, usefulness or timeliness.

Printing is only available to North Data premium service subscribers.